MacroGenics Q1 2025 Update: Revenue Streams Detailed
Ticker: MGNX · Form: 10-Q · Filed: 2025-05-13T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, revenue, pharmaceutical
TL;DR
MGNX Q1 2025: Revenue breakdown from collaborations, products, and manufacturing. Balance sheet details from end of 2024.
AI Summary
MacroGenics Inc. reported its first quarter 2025 results for the period ending March 31, 2025. The company's financial filings indicate revenue from collaborative agreements and product sales, alongside contract manufacturing and government contracts. Specific financial figures for these revenue streams and balance sheet items like common stock and retained earnings as of December 31, 2024, are detailed within the report.
Why It Matters
This filing provides investors with a snapshot of MacroGenics' financial performance and revenue sources for the first quarter of 2025, crucial for understanding the company's operational health.
Risk Assessment
Risk Level: medium — The company operates in the pharmaceutical sector, which is inherently subject to regulatory, clinical trial, and market risks.
Key Numbers
- 2025 Q1 — Reporting Period (First quarter of 2025)
- 2024-12-31 — Balance Sheet Date (End of fiscal year 2024)
Key Players & Entities
- MACROGENICS INC (company) — Filer
- 20250331 (date) — Reporting Period End Date
- 20250513 (date) — Filing Date
- 2024-12-31 (date) — Prior Period Balance Sheet Date
FAQ
What were MacroGenics' total revenues from collaborative agreements for the first quarter of 2025?
The filing indicates revenue from collaborative agreements for the period January 1, 2025, to March 31, 2025, but the specific dollar amount is not provided in this excerpt.
How did product revenue in Q1 2025 compare to Q1 2024 for MacroGenics?
The filing shows product revenue for both Q1 2025 and Q1 2024, but the specific dollar amounts are not detailed in this section.
What is the company's fiscal year end?
MacroGenics Inc.'s fiscal year ends on December 31.
What is the SIC code for MacroGenics Inc.?
The Standard Industrial Classification code for MacroGenics Inc. is 2834, Pharmaceutical Preparations.
What are the key balance sheet components reported as of December 31, 2024?
Key balance sheet components reported as of December 31, 2024, include Common Stock, Additional Paid-In Capital, Retained Earnings, and Accumulated Other Comprehensive Income (AOCI).
From the Filing
0001125345-25-000053.txt : 20250513 0001125345-25-000053.hdr.sgml : 20250513 20250513160118 ACCESSION NUMBER: 0001125345-25-000053 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 54 CONFORMED PERIOD OF REPORT: 20250331 FILED AS OF DATE: 20250513 DATE AS OF CHANGE: 20250513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MACROGENICS INC CENTRAL INDEX KEY: 0001125345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36112 FILM NUMBER: 25939797 BUSINESS ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: Rockville STATE: MD ZIP: 20850 BUSINESS PHONE: 301-251-5172 MAIL ADDRESS: STREET 1: 9704 MEDICAL CENTER DRIVE CITY: ROCKVILLE STATE: MD ZIP: 20850 10-Q 1 mgnx-20250331.htm 10-Q mgnx-20250331 FALSE 2025 Q1 0001125345 --12-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares mgnx:productCandidate xbrli:pure mgnx:performanceObligation mgnx:segment 0001125345 2025-01-01 2025-03-31 0001125345 2025-05-09 0001125345 2025-03-31 0001125345 2024-12-31 0001125345 mgnx:RevenueFromCollaborativeAgreementsMember 2025-01-01 2025-03-31 0001125345 mgnx:RevenueFromCollaborativeAgreementsMember 2024-01-01 2024-03-31 0001125345 us-gaap:ProductMember 2025-01-01 2025-03-31 0001125345 us-gaap:ProductMember 2024-01-01 2024-03-31 0001125345 mgnx:ContractManufacturingMember 2025-01-01 2025-03-31 0001125345 mgnx:ContractManufacturingMember 2024-01-01 2024-03-31 0001125345 us-gaap:GovernmentContractMember 2025-01-01 2025-03-31 0001125345 us-gaap:GovernmentContractMember 2024-01-01 2024-03-31 0001125345 2024-01-01 2024-03-31 0001125345 us-gaap:CommonStockMember 2024-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001125345 us-gaap:RetainedEarningsMember 2024-12-31 0001125345 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001125345 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001125345 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2025-01-01 2025-03-31 0001125345 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001125345 us-gaap:CommonStockMember 2025-03-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001125345 us-gaap:RetainedEarningsMember 2025-03-31 0001125345 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2025-03-31 0001125345 us-gaap:CommonStockMember 2023-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001125345 us-gaap:RetainedEarningsMember 2023-12-31 0001125345 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2023-12-31 0001125345 2023-12-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001125345 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001125345 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-01-01 2024-03-31 0001125345 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001125345 us-gaap:CommonStockMember 2024-03-31 0001125345 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001125345 us-gaap:RetainedEarningsMember 2024-03-31 0001125345 us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember 2024-03-31 0001125345 2024-03-31 0001125345 2020-08-14 2025-03-31 0001125345 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2025-03-31 0001125345 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2025-03-31 0001125345 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2025-03-31 0001125345 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2025-03-31 0001125345 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2025